Metsera, Inc.

Metsera, Inc.

MTSR·NASDAQ

$70.50

+0.0000%
HealthcareBiotechnology

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.

At a Glance

Live Snapshot
Market Cap$7.43B
EPS-2.0300
P/E Ratio-34.73
Earnings Date03/25/2026

No Dividend Yield Data

MTSR has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

MTSR has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

MTSR has not reported any net dividends paid values in the available annual periods.

Metsera, Inc.

Metsera, Inc. Dividend History

MTSR · NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

MTSR Dividend Payment History

MTSR · NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
mtsr

Metsera, Inc. Payout Ratio Analysis

MTSR · NASDAQ
Dividends Paid
0.00
2024
Net Income
-209.13M
2024
Payout Ratio
0.00%
2024

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.